Alan Ezekowitz Acquires 7,491 Shares of Septerna, Inc. (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) Director Alan Ezekowitz acquired 7,491 shares of Septerna stock in a transaction on Tuesday, March 4th. The shares were purchased at an average cost of $6.35 per share, with a total value of $47,567.85. Following the completion of the purchase, the director now directly owns 24,911 shares of the company’s stock, valued at approximately $158,184.85. This represents a 43.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Alan Ezekowitz also recently made the following trade(s):

• On Thursday, March 6th, Alan Ezekowitz acquired 41,355 shares of Septerna stock. The shares were purchased at an average cost of $6.00 per share, with a total value of $248,130.00.

Septerna Stock Performance

NASDAQ:SEPN opened at $6.43 on Friday. The stock has a 50 day moving average price of $14.47. Septerna, Inc. has a 52 week low of $4.17 and a 52 week high of $28.99.

Analyst Ratings Changes

A number of analysts have commented on SEPN shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $50.00 price objective on shares of Septerna in a research note on Tuesday, February 11th. Wells Fargo & Company downgraded Septerna from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $43.00 to $14.00 in a report on Tuesday, February 18th. TD Cowen initiated coverage on Septerna in a report on Tuesday, November 19th. They issued a “buy” rating on the stock. Finally, JPMorgan Chase & Co. initiated coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock.

Hedge Funds Weigh In On Septerna

A number of hedge funds have recently added to or reduced their stakes in SEPN. Tower Research Capital LLC TRC acquired a new position in Septerna in the fourth quarter worth approximately $25,000. New York State Common Retirement Fund acquired a new position in Septerna in the fourth quarter worth approximately $32,000. Legal & General Group Plc acquired a new position in Septerna in the fourth quarter worth approximately $42,000. Summit Investment Advisors Inc. bought a new stake in Septerna during the fourth quarter worth approximately $45,000. Finally, BNP Paribas Financial Markets bought a new stake in Septerna during the fourth quarter worth approximately $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.